Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

HIV-1 Infection Clinical Trial

— SWIFT-C  

Official title:

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02128217
• Other study ID #: ACTG A5327
• Secondary ID: UM1AI068636
• Status: Completed
• Phase: Phase 1
• First received: April 29, 2014
• Last updated: March 29, 2018
• Start date: May 30, 2014
• Est. completion date: May 9, 2017

Study information

• Verified date: March 2018
• Source: AIDS Clinical Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Early identification of acute HCV infection is essential to prevent chronic infections and the long-term liver disease complications that may occur. Early identification and treatment of HCV during the acute phase can result in significantly higher response rates with shorter durations of therapy.

Pegylated-interferon alfa (PEG-IFN) was the typical treatment for HCV infection. Participants subcutaneously inject PEG-IFN where the average duration of treatment was approximately 20 weeks. With the advancement of direct-acting antivirals (DAAs), it was possible to see if a new DAA might be non-inferior compared to (PEG-IFN).

The study was designed to see if a fixed-dose combination tablet can replace the old HCV treatments by being more effective, safer and better tolerated in HIV-infected participants with new HCV infection. The study was a Phase I, open-label, two cohort clinical trial, in which 44 acutely HCV-infected HIV-1 positive participants were enrolled. Participants in each cohort were evaluated in two steps: on treatment (Step 1) and follow-up after discontinuing study treatment (Step 2). The cohorts were enrolled sequentially. Participants in Cohort 1 were enrolled and administered oral Sofosbuvir (SOF) in combination with weight-based ribavirin (RBV). Participants in Cohort 2 were enrolled and administered an oral fixed dose combination of Ledipasvir/Sofosbuvir (LDV/SOF).

Description:

The first cohort opened with SOF/RBV treatment for 12 weeks and accrued 17 participants. All participants under Cohort 1 were to visit the clinical site at weeks 0, 1, 2, 4, 8, and 12 when on treatment (Step 1), then visit the clinical site again at 2, 4, 8, 12 and 24 weeks during follow-up after discontinuing study treatment (Step 2).

The second cohort opened for an 8-week treatment of LDV/SOF and included at least 27 subjects. All participants under Cohort 2 were to visit the clinical site at weeks 0, 1, 2, 4, and 8 when on treatment (Step 1), then visit the clinical site again at 2, 4, 8, 12 and 24 weeks during follow-up after discontinuing study treatment (Step 2).

Both cohorts were monitored for safety and HCV viral load response while the participants were on treatment.

The primary objective did not compare the cohorts together; instead, each study cohort was formally assessed for efficacy with sustained virologic response 12 weeks after treatment based on non-inferiority criteria compared to a historical SVR rate of 60% separately.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: May 9, 2017
• Est. primary completion date: February 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

A5327 Eligibility Criteria (Cohort 1 and Cohort 2)

Step 1 inclusion criteria for both cohorts (Cohort 1 and Cohort 2)

• HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 p24 antigen, or plasma HIV-1 RNA viral load. [NOTE: The term "licensed" refers to a FDA-approved kit, which is required for all IND studies.] WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.

• A documented confirmation of acute HCV infection within 6 months prior to A5327 entry or HCV reinfection as described below:

1. Acute HCV infection was defined as meeting one of the following criteria and exclusion of other causes of acute hepatitis:

• New (<24 weeks prior to initial A5327 entry) ALT elevation to =5X upper limit of normal (ULN) OR >250 U/L in patients with documented normal ALT in the preceding 12 months or =10X ULN OR >500 U/L in patients with abnormal or no measured ALT baseline in the preceding 12 months with detectable HCV RNA excluding those with any prior positive anti-HCV. OR

• Detectable HCV RNA with prior negative anti-HCV Ab or undetectable HCV RNA within the preceding 6 months.

2. Acute HCV reinfection was defined by documentation of clearance of prior infection (as evidenced by positive anti-HCV Ab) either spontaneously or after treatment with two negative HCV RNA a minimum of 6 months apart AND meeting one of the following criteria in addition to exclusion of other causes of acute hepatitis:

• New (<24 weeks prior to initial A5327 entry) ALT elevation to =5X ULN OR >250 U/L in patients with documented normal ALT in the preceding 12 months or =10X ULN OR >500 U/L in patients with abnormal or no measured ALT baseline in the preceding 12 months with detectable HCV RNA. OR

• Positive HCV RNA with prior negative HCV RNA within the preceding 6 months.

• HCV RNA confirmed to be detectable >12 weeks after first laboratory evidence of acute HCV and still within the <24 week from first laboratory evidence of acute HCV infection window. First laboratory evidence of infection was defined as date of first elevated liver enzymes or date of first serologic evidence of HCV seroconversion and/or viremia (whichever occurs first). [NOTE: If the screening visit occurred less than 12 weeks from the first laboratory evidence of infection, then the participant was required a pre-entry study visit to confirm detectable HCV RNA at least 12 weeks from the first laboratory evidence of infection had passed. It was optimal for this pre-entry visit to occur as close as possible to 12 weeks from first laboratory evidence to ensure timely treatment. Potential participants who entered screening but who had an undetectable HCV RNA (<LLOQ TND) at the pre-entry visit (when required) exhibited evidence of possible spontaneous clearance and will not meet the entry criteria.]

• Body mass index (BMI) = 18 kg/m^2

• Screening electrocardiogram (ECG) without clinically significant abnormalities as determined by the investigator.

• Willing and able to provide written informed consent.

• Men and women age = 18 years.

• All participants agreed not to participate in a conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). [NOTE: Female candidates who were pregnant or breastfeeding were not eligible. A male candidate who had a pregnant female partner was not eligible for the study.]

• When participating in sexual activity that could lead to pregnancy, all participants must agree to use at least two reliable forms of contraceptive simultaneously while receiving protocol-specified medications, and for 6 months after stopping the medications. Such methods included:

• Condoms (male or female) with or without a spermicidal agent

• Diaphragm or cervical cap with spermicide

• Intrauterine device (IUD)

• Tubal ligation

• Hormone-based contraceptive (except those containing drospirenone)

[NOTE: Providers and participants were advised that not all contraceptive choices listed above can prevent HIV transmission and that some may actually increase the risk of HIV acquisition. Study participants who were sexually active with HIV-1 negative or unknown HIV-1 serostatus partners were advised that they needed to consider effective strategies for reducing the risk of HIV transmission, as well as meeting the requirement for effective contraception during their participation in the study. Study participants discussed contraceptive choices and HIV risk reduction methods with their health care provider.]

• Participants who were not of reproductive potential (women who had been post-menopausal for at least 24 consecutive months or had undergone hysterectomy and/or bilateral oophorectomy or salpingectomy or men who had documented azoospermia or undergone vasectomy) were eligible without requiring the use of contraceptives. Acceptable documentation of sterilization and menopause was specified below.

• Written or oral documentation communicated by clinician or clinician's staff of one of the following:

• Physician report/letter

• Operative report or other source documentation in the patient record (a laboratory report of azoospermia was required to document successful vasectomy)

• Discharge summary

• Follicle stimulating hormone-release factor (FSH) measurement elevated into the menopausal range as established by the reporting laboratory.

• Intention to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.

Step 1 inclusion criteria for Cohort 1 only

• HIV-1 ARV therapy fell into one of the following criteria:

1. ARV untreated, for example due to (1) lack of indication per provider (CD4 T-cell count >500 cells/mm3) or (2) decision by provider and participant to defer ARV therapy during the study drug dosing period (8 or 12 weeks), or (3) elite controller (CD4+ >200 cells/mm3). OR

2. On a stable, protocol-approved (didanosine (ddI), stavudine (d4T), zidovudine (ZDV) excluded), ARV regimen for >8 weeks prior to screening with a CD4 T-cell count >200 cells/mm3 and a documented plasma HIV-1 RNA level <50 copies/mL or < lower limit of quantification (LLOQ) of local assay if LLOQ is >50 copies/mL by any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent = 8 weeks preceding the A5327 screening visit. HIV-1 RNA levels should be within 1 year of the screening visit. Screening HIV-1 RNA must be < 50 copies/mL as measured by any local laboratory using an FDA-approved assay.

• Candidates must have had the following laboratory parameters within 10-42 days prior to study entry:

1. Hemoglobin = 12 g/dL for male, =11 g/dL for female participants

2. International normalized ratio (INR) =1.5 x ULN unless participant was known hemophilia or was stable on an anticoagulant regimen affecting INR

3. Albumin = 3 g/dL

4. Creatinine clearance (CrCl) = 60 mL/min, as calculated by the Cockcroft-Gault equation (refer to section 6.3.5 for calculator utility link)

• Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who had not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy) must had a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL performed during screening, within 48 hours prior to study entry.

Step 1 inclusion criteria for Cohort 2 only

• HCV genotype 1a, 1b, or 4 infection with source documentation from a CLIA-approved laboratory (or its equivalent). [NOTE: Those with mixed 1a/b genotype were classified as 1a.]

• HIV-1 ARV therapy fell into one of the following criteria:

1. ARV untreated, for example due to (1) lack of indication per provider (CD4 T-cell count >500 cells/mm3) or (2) decision by provider and participant to defer ARV therapy during the study drug dosing period (8 or 12 weeks), or (3) elite controller (CD4+ >200 cells/mm3). OR

2. On a stable, protocol-approved ARV regimen (the following ARVs are not allowed:

ddI, d4T, and TPV/r) for >8 weeks prior to screening with a CD4 T-cell count >200 cells/mm3 and a documented plasma HIV-1 RNA level <50 copies/mL or <LLOQ of local assay if LLOQ is >50 copies/mL by any laboratory that had a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent = 8 weeks preceding the A5327 screening visit. HIV-1 RNA levels should be within 1 year of the screening visit. Screening HIV-1 RNA must be <50 copies/mL as measured by any local laboratory using an FDA-approved assay.

• Candidates must have had the following laboratory parameters within 10-42 days prior to study entry:

1. Hemoglobin =9 g/dL for male and female participants

2. International normalized ratio (INR) =1.5 x ULN unless participant had known hemophilia or wass stable on an anticoagulant regimen affecting INR

3. Albumin =3 g/dL

4. Creatinine clearance (CrCl) =60 mL/min, as calculated by the Cockcroft-Gault equation (refer to section 6.3.5 for calculator utility link)

• Female participants of reproductive potential (defined as women who had not been post-menopausal for at least 24 consecutive months, ie, who had menses within the preceding 24 months, or women who had not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy) must had a negative serum or urine pregnancy test within 48 hours prior to study entry by any laboratory or clinic that had a CLIA certificate or its equivalent, or was using a point-of-care (POC)/CLIA-waived test. The serum, urine or POC pregnancy test must had a sensitivity of at least 25 mIU/mL.

Step 1 exclusion criteria for both cohorts (Cohort 1 and Cohort 2)

• Received investigational drug or device within 60 days prior to study entry.

• Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, a1 antitrypsin deficiency, primary sclerosing cholangitis).

• Presence of active or acute AIDS-defining opportunistic infections within 30 days prior to study entry. [NOTE: A list of AIDS-defining opportunistic infections as defined by the CDC, can be found in Appendix B of the following document: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm]

• Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics, antivirals, or antifungals within 30 days prior to study entry.

• Infection with hepatitis B virus (HBV) defined as HBsAg positive.

• Evidence of acute hepatitis A infection defined as HAV IGM positive.

• Chronic use of systemically administered immunosuppressive agents (eg, prednisone equivalent > 10 mg/day).

• History of solid organ transplantation.

• Current or prior history of clinical hepatic decompensation (eg, ascites, encephalopathy or variceal hemorrhage).

• History of a gastrointestinal disorder (or post operative condition) that could interfere with the absorption of the study drug.

• History of significant or symptomatic pulmonary disease, cardiac disease, or porphyria.

• History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.

• History of clinically significant illness or any other major medical disorder that may interfere with participant treatment, assessment, or compliance with study requirements, which may included active drug or alcohol use or dependence.

• Use of any prohibited concomitant medications within 30 days prior to study entry.

• Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable. [NOTE: Participants with early infection, defined as within the first 6 months of infection and with a positive HIV antibody, should be discussed with the A5327 protocol core team. These participants may be considered for inclusion in the study on a case by case basis with the specific documented approval of the protocol chairs.]

Step 1 exclusion criteria for Cohort 1 only

• Prior exposure to a direct-acting antiviral (DAA) targeting the HCV NS5B polymerase. [NOTE: DAAs include but are not limited to: mericitabine, ABT-333, ABT-072, BI-207127, BMS-791325, VX-222, tegobuvir, IDX719, setrobuvir, GS-9669, VX-135.]

• History of clinically significant hemoglobinopathy (eg, sickle cell disease, thalassemia).

• Known hypersensitivity to RBV, SOF, its metabolites, or formulation excipients or any other contraindication to the use of RBV or SOF.

• Currently receiving ZDV, ddI, or d4T.

Step 1 Exclusion criteria for Cohort 2 only

• Any preceding attempt at HCV treatment during this acute HCV infection episode, ie, 24 weeks prior to entry.

• Known hypersensitivity to SOF or LDV, the metabolites, or formulation excipients or any other contraindication to the use of SOF or LDV.

• Currently receiving TPV/r, ddI, d4T or amiodarone.

• Pregnancy or Breastfeeding.

Related Conditions & MeSH terms

• Hepatitis
• HIV-1 Infection
• Infection

Intervention

Drug:
• Sofosbuvir
Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
• Ribavirin
Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
• Ledipasvir/Sofosbuvir
Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.

Locations

Country	Name	City	State
United States	101 Massachusetts General Hospital (MGH) CRS	Boston	Massachusetts
United States	2701 Northwestern University CRS	Chicago	Illinois
United States	Rush Univ. Med. Ctr. ACTG CRS (2702)	Chicago	Illinois
United States	2401 Cincinnati CRS	Cincinnati	Ohio
United States	31443 Trinity Health and Wellness Center CRS	Dallas	Texas
United States	31473 Houston AIDS Research Team (HART) CRS	Houston	Texas
United States	7803 Weill Cornell Upton CRS	New York	New York
United States	7804 Weill Cornell Chelsea CRS	New York	New York
United States	6201 Penn Therapeutics CRS	Philadelphia	Pennsylvania
United States	701 University of California, San Diego AntiViral Research Center CRS	San Diego	California
United States	801 University of California, San Francisco HIV/AIDS CRS	San Francisco	California
United States	Whitman Walker Health CRS (31791)	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
AIDS Clinical Trials Group	National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Sustained Virologic Response 12 (SVR12)	SVR12 was defined as HCV RNA undetectable less than the lower limit of quantification, Target Not Detected (For both Cohort 1 and Cohort 2, the 12 week measurement used for determining SVR12 was the measurement obtained closest to 84 days (i.e. 12*7 days), within the window 79 to 112 days inclusive. If a participant did not have an HCV RNA measurement within this window, then the participant was considered as having detectable HCV RNA at 12 weeks unless the preceding and subsequent HCV RNA measurements were both undetectable (A two-sided 90% confidence interval was calculated for this percentage using the Blyth-Still-Casella method.	At 12 weeks after date of last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Primary	Percentage of Participants With an Occurrence of a Grade = 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE.	Any adverse event occurring after initiation of study treatment through to 28 days after the date of last dose of study treatment was included (except that an event that was ongoing at the same grade from before start of study treatment was excluded). Adverse events consisted of Grade = 2 primary diagnosis, primary sign/symptoms, and primary laboratory abnormality. It also included any serious adverse event according to ICH criteria and any treatment-limiting AE (ie, an AE reported as the reason for permanent discontinuation of study treatment).; A two-sided 90% confidence interval was calculated for the percentage using the Blyth-Still-Casella method.	From initiation of study treatment to 28 days after last dose of study treatment. The duration for study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Secondary	Percentage of Participants With HCV RNA Undetectable During Study Treatment	HCV RNA undetectable was defined as an HCV RNA measurement A two-sided 90% confidence interval was calculated for each proportion using the Blyth-Still-Casella method.	1, 2, 4, 8 and, for the 12-week regimen, 12 weeks after starting study treatment.
Secondary	Percentage of Participants With HCV RNA Undetectable After End of Study Treatment	HCV RNA undetectable is defined as an HCV RNA measurement A two-sided 90% confidence interval was calculated for the percentage using the Blyth-Still-Casella method.	2, 4, 8 and 24 weeks after last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Secondary	Number of Participants Who Had HCV Virologic Relapse	HCV virologic relapse was defined as HCV RNA undetectable at end-of-treatment but HCV RNA quantifiable during follow-up with subsequent confirmation as quantifiable.	From end of study treatment through to 24 weeks after end of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Secondary	Percentage of HCV Virologic Failure Participants That Developed SOF- or LDV-Associated Resistance Mutations	Percentage of participants who developed SOF- or LDV-associated resistance mutation found within HCV Virologic Failure participants. HCV virologic failure was defined as HCV RNA undetectable at end-of-treatment but HCV RNA quantifiable during follow-up with subsequent confirmation as quantifiable.	At time of HCV virologic failure; any time from start of study treatment to 24 weeks after end of study treatment. Duration of study treatment for Cohort 1 and 2 were 12 and 8 weeks, respectively.
Secondary	Count and Percentage of Participants With an Adverse Event by Type.	The adverse events considered were Grade 2 or higher adverse events (primary diagnosis, primary sign and symptom, or a primary lab), SAE according to ICH criteria, or treatment-limiting adverse events. Participants may experience more than one type of adverse event.	Any time from start of treatment to 28 days after date of last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Secondary	Count of Participants With HIV-1 RNA <50 Copies/mL	Because all except one participant had HIV-1 RNA < 50 copies/mL, participants were categorized according to whether or not their HIV-1 RNA was <5 copies/mL at each follow-up evaluation.	4 and 12 weeks after start of study treatment for Cohort 1. 4 and 8 weeks after start of study treatment for the 8-week regimen used in Cohort 2)
Secondary	Change in CD4+ Cell Count	The change in CD4+ cell count from baseline to 12 weeks after the end of study treatment.	Baseline to 12 weeks after end of study treatment. Duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Secondary	Self-reported Adherence to SOF	Count and percentage of participants who reported having taken all doses of SOF. This outcome measure was evaluated in Cohort 1 only.	1, 2, 4, 8 and 12 weeks after starting study treatment.
Secondary	Adherence as Measured by SOF Pill Count	The count and percentage of participants who had a pill count consistent with 100% of SOF doses taken. This outcome measure was evaluated in Cohort 1 only.	12 weeks after starting study treatment.
Secondary	Self-reported Adherence to RBV	Count and percentage of participants who reported having taken all doses of RBV. This outcome measure was evaluated in Cohort 1 only.	1, 2, 4, 8 and 12 weeks after starting study treatment.
Secondary	Adherence as Measured by RBV Pill Count	The count and percentage of participants who had a pill count consistent with 100% of RBV doses taken. This outcome measure was evaluated in Cohort 1 only.	12 weeks after starting study treatment.
Secondary	Self-reported Adherence to LDV/SOF	Count and percentage of participants who reported having taken all doses of LDV/SOF. This outcome measure was evaluated in Cohort 2 only.	1, 2, 4, and 8 weeks after starting study treatment.
Secondary	Adherence as Measured by LDV/SOF Pill Count	The count and percentage of participants who had a pill count consistent with 100% of LDV/SOF doses taken.. This outcome measure was evaluated in Cohort 2 only.	8 weeks after starting study treatment.
Secondary	Ribavirin Concentration in Plasma	Ribavirin concentration in plasma. This outcome was evaluated in Cohort 1 only.	4, 8, and 12 weeks after starting study treatment.
Secondary	Cellular Concentration of Tenofovir Diphosphate (TFV-DP)	Cellular concentration of tenofovir diphosphate (TFV-DP) from dried blood spot samples.	Baseline (before HCV study treatment), EOT (end of trial dosing), 12 weeks after end of HCV study treatment. The duration of HCV study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Secondary	Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs)	Concentration of tenofovir diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs). This outcome is measured in Cohort 1 only.	Baseline (before SOF + RBV dosing), EOT (end of study treatment), 12 weeks after end of HCV study treatment.
Secondary	Concentration of Tenofovir (TFV) in Plasma	Concentration of tenofovir (TFV) in plasma among participants who took TFV for treatment of HIV infection.	Baseline (before HCV study treatment), EOT (end of trial dosing), 12 weeks after end of HCV study treatment. The duration of HCV study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.

External Links

•   Aids Clinical Trial Group Network
•   The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 2.0, November 2014